The role of interleukin-13 in the management of atopic dermatitis: an expert consensus panel
DOI:
https://doi.org/10.5070/tvshr813Keywords:
atopic dermatitis, biologics, dupilumab, interleukin-13, lebrikizumab, new therapies, tralokinumabAbstract
Atopic dermatitis is a chronic inflammatory skin condition driven by immune dysregulation, with interleukin-13 playing a central role in its pathogenesis. Recent advances in targeted biologic therapies have shown promising results in treating moderate-to-severe atopic dermatitis. A comprehensive literature review of PubMed and Google Scholar was conducted to identify studies related to interleukin-13 inhibition in atopic dermatitis. An expert panel reviewed and graded the evidence using Strength of Recommendation Taxonomy criteria and utilized a modified Delphi process to formulate consensus statements on the role of interleukin-13 inhibitors. Based on selected literature, the panel developed 14 consensus statements, all receiving unanimous approval. Key findings include the rapid efficacy, sustained benefits, and favorable safety profiles of interleukin-13 inhibitors. Differences between available interleukin-13 inhibitors included pain of injection, speed of onset, durability of efficacy, and number of injections needed to maintain efficacy. Interleukin-13 plays a pivotal role in atopic dermatitis pathogenesis, driving inflammation, pruritus, and barrier dysfunction. Targeted therapies, including interleukin-13 inhibitors, provide rapid, durable, and safe options for managing moderate-to-severe atopic dermatitis. This consensus highlights interleukin-13 inhibition as a cornerstone in advancing atopic dermatitis treatment strategies, offering improved patient outcomes and quality of life.
Downloads
References
1. Napolitano M, di Vico F, Ruggiero A, Fabbrocini G, Patruno C. The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis. Front Med. 2023;10:1165098. [PMID: 37144036].
2. Obara W, Kawa Y, Ra C, Nishioka K, Soma Y, Mizoguchi M. T cells and mast cells as a major source of interleukin-13 in atopic dermatitis. Dermatol Basel Switz. 2002;205(1):11-17. [PMID: 12145428].
3. Furue K, Ito T, Tsuji G, et al. The IL-13-OVOL1-FLG axis in atopic dermatitis. Immunology. 2019;158(4):281-286. [PMID: 31509236].
4. Furue M. Regulation of skin barrier function via competition between AHR axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 axis: Pathogenic and therapeutic implications in atopic dermatitis. J Clin Med. 2020;9(11):3741. [PMID: 33233866].
5. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): A patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004;17(1):59-67. [PMID: 15014055].
6. Hsu CC, Sandford BA. The Delphi technique: Making sense of consensus. Pract Assess Res Eval. 2007;12(1). [DOI:10.7275/pdz9-th90].
7. Berman B, Ceilley R, Cockerell C, et al. Appropriate use criteria for the integration of diagnostic and prognostic gene expression profile assays into the management of cutaneous malignant melanoma: An expert panel consensus-based modified Delphi process assessment. SKIN J Cutan Med. 2019;3(5):291-306. [DOI:10.25251/skin.3.5.1].
8. Burshtein J, Shah M, Zakria D, et al. The efficacy and safety of Bimekizumab for plaque psoriasis: An expert consensus panel. Dermatol Ther. 2024;14(2):323-339. [PMID: 38340237].
9. Zakria D, Shah M, Burshtein J, et al. The role of field cancerization in selecting therapies for actinic keratosis: An expert consensus panel. SKIN J Cutan Med. 2024;8(3):1478-1487. [DOI:10.25251/skin.8.3.1].
10. Bitton A, Avlas S, Reichman H, et al. A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis. Sci Immunol. 2020;5(44):eaaw2938. [PMID: 32060143].
11. Purwar R, Werfel T, Wittmann M. IL-13-stimulated human keratinocytes preferentially attract CD4+CCR4+ T cells: Possible role in atopic dermatitis. J Invest Dermatol. 2006;126(5):1043-1051. [PMID: 16484990].
12. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54-62. [PMID: 31230370].
13. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129(3):742-751. [PMID: 18830273].
14. Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of Lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080-1091. [PMID: 36920778].
15. Simpson E, Fernández-Peñas P, de Bruin-Weller M, et al. Improvement across dimensions of disease with Lebrikizumab use in atopic dermatitis: Two phase 3, randomized, double-blind, placebo-controlled monotherapy trials (ADvocate1 and ADvocate2). Adv Ther. 2025;42(1):144-145. [PMID: 39249591].
16. Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740-748. [PMID: 36994947].
17. Paller AS, Flohr C, Eichenfield LF, et al. Safety and efficacy of Lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: A 52-week, open-label, phase 3 study. Dermatol Ther (Heidelb). 2023;13(7):1517-1534. [PMID: 37318750].
18. Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437-449. [PMID: 33000465].
19. Blauvelt A, Gooderham M, Bhatia N, et al. Tralokinumab efficacy and safety, with or without topical corticosteroids, in North American adults with moderate-to-severe atopic dermatitis: A subanalysis of phase 3 trials ECZTRA 1, 2, and 3. Dermatol Ther (Heidelb). 2022;12(11):2499-2516. [PMID: 36152216].
20. Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: Pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022;187(6):888-899. [PMID: 36082590].
21. Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. [PMID: 29353026].
22. Yim HJ, Jean T, Ong PY. Comparison of old and new systemic treatments for moderate to severe atopic dermatitis. Curr Allergy Asthma Rep. 2024;24(5):289-301. [PMID: 38632138].
23. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43-e56. [PMID: 37943240].
24. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349. [PMID: 24813298].
25. Zhang Y, Jing D, Cheng J, Chen X, Shen M, Liu H. The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis. Front Immunol. 2022;13:923362. [PMID: 35967348].
26. Drucker AM, Lam M, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: Living systematic review and network meta-analysis update. JAMA Dermatol. 2024;160(9):936-944. [PMID: 39018058].
27. Schneeweiss MC, Glynn RJ, Wyss R, et al. A scalable approach to assess the safety of recently marketed systemic treatments for atopic dermatitis in clinical practice: First analysis cycle of a sequential monitoring system. J Invest Dermatol. 2025;145(5):1070-1080. [PMID: 39362623].
28. Chu AWL, Wong MM, Rayner DG, et al. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1470-1492. [PMID: 37678577].
29. Chang PH, Huang SF, Chang PS, Yu Y. Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications. J Dermatol. 2021;48(11):1631-1639. [PMID: 34462967].
30. Simpson EL, de Bruin-Weller M, Hong HC ho, et al. Lebrikizumab provides rapid clinical responses across all eczema area and severity index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis. Dermatol Ther. 2024;14(5):1145-1160. [PMID: 38700646].
31. Napolitano M, Fabbrocini G, Patruno C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study. J Dermatol. 2023;50(7):880-887. [PMID: 36914982].
32. Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol. 2021;84(5):1339-1347. [PMID: 33428978].
33. DailyMed - DUPIXENT- dupilumab injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=595f437d-2729-40bb-9c62-c8ece1f82780. Accessed December 27, 2024.
34. García-González S, Villagrasa-Boli P, Bularca E, Moratiel-Pellitero A, Prieto-Torres L. Tralokinumab-related facial redness: A therapeutic challenge. Int J Dermatol. 2024;63(11):1605-1606. [PMID: 38842180].
35. DailyMed - EBGLYSS- lebrikizumab-lbkz injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f. Accessed December 27, 2024.
36. Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of Lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: A randomized clinical trial (ADhere). JAMA Dermatol. 2023;159(2):182-191. [PMID: 36630140].
37. Simpson EL, Guttman-Yassky E, Eichenfield LF, et al. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition. Allergy. 2023;78(11):2875-2891. [PMID: 37455359].
38. Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135-141. [PMID: 29906525].
39. Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of Lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: A phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411-420. [PMID: 32101256].
40. Katoh N, Tanaka A, Takahashi H, et al. Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: A 68-week, randomized, double-blind, placebo-controlled phase III trial in Japan (ADhere-J). Br J Dermatol. 2025 Mar 18;192(4):597-610. [PMID: 39442013].
41. Silverberg JI, Wollenberg A, Stein Gold L, et al. Patients with moderate-to-severe atopic dermatitis maintain stable response with no or minimal fluctuations with 1 year of Lebrikizumab treatment. Dermatol Ther (Heidelb). 2024;14(8):2249-2260. [PMID: 39123054].
42. Rand K, Ramos-Goñi JM, Akmaz B, Solé-Feu L, Armario-Hita JC. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of Lebrikizumab versus Dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14(1):169-182. [PMID: 37897645].
43. Simpson EL, Pink AE, Blauvelt A, et al. Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: Pooled data from two phase III trials. Am J Clin Dermatol. 2023;24(6):939-952. [PMID: 37682422].
44. Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815-824. [PMID: 35863467].
45. Chiricozzi A, Ferrucci SM, Di Nardo L, et al. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: Results from a multicentric, multinational, retrospective, cohort study. Expert Opin Biol Ther. 2023;23(12):1307-1315. [PMID: 38108300].
46. Silverberg JI, Ackerman L, Bagel J, Stein Gold L, et al. Lebrikizumab improves atopic dermatitis and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab: Results from the ADapt trial [poster]. J of Skin. 2025;9(1):s512. [DOI:10.25251/skin.9.supp.512].
47. Lio PA, Armstrong A, Gutermuth J, et al. Lebrikizumab improves quality of life and patient-reported symptoms of anxiety and depression in patients with moderate-to-severe atopic dermatitis. Dermatol Ther. 2024;14(7):1929-1943. [PMID: 38922484].
48. Yosipovitch G, Lio P, Legat FJ, et al. Stable response and sustained improvement of itch and sleep symptoms in patients with atopic dermatitis treated with Lebrikizumab over 52 weeks. Dermatol Ther. 2024;14(8):2171-2180. [PMID: 39002092].
49. Merola JF, Bagel J, Almgren P, et al. Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2021;85(1):71-78. [PMID: 33744356].
50. Soung J, Laquer V, Merola JF, et al. The impact of Lebrikizumab on vaccine-induced immune responses: Results from a phase 3 study in adult patients with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14(8):2181-2193. [PMID: 39009804].
51. Lieberman JA, Chu DK, Ahmed T, et al. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2024;133(3):286-294. [PMID: 38848870].
52. Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential risks related to modulating interleukin-13 and interleukin-4 signalling: A systematic review. Drug Saf. 2018;41(5):489-509. [PMID: 29411337].
53. Foerster J, Molęda A. Feasibility analysis of interleukin-13 as a target for a therapeutic vaccine. Vaccines. 2019;7(1):20. [PMID: 30759882].
54. Alves C, Penedones A, Mendes D, Batel Marques F. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and network meta-analysis. Eur J Clin Pharmacol. 2022;78(12):1923-1933. [PMID: 36207461].
55. Napolitano M, Di Guida A, Fabbrocini G, Patruno C. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience. Dermatol Ther. 2021;34(5):e15059. [PMID: 34241938].
56. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459-473. [PMID: 30851191].
57. Wollenberg A, Beck LA, de Bruin Weller M, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: Results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453-465. [PMID: 34637142].
58. Stein Gold L, Thaçi D, Thyssen JP, et al. Safety of Lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: An integrated analysis of eight clinical trials. Am J Clin Dermatol. 2023;24(4):595-607. [PMID: 37195407].
59. Guttman-Yassky E, Kabashima K, Staumont-Salle D, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024;79(6):1560-1572. [PMID: 38563683].
60. Guttman-Yassky E, Okragly A, Sun Z, Nickoloff BJ, Preuss C, Natalie CR, et al. Lebrikizumab treatment results in rapid improvement of atopic dermatitis disease cytokines and pathways. Journal of Investigative Dermatology.
61. Guttman-Yassky E, Okragly A, Sun Z, Mena LR, Hahn N, Nickoloff BJ, et al. Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis. British Journal of Dermatology. 2024;190(Supplement_2):ii4-ii5. [DOI: 10.1093/bjd/ljad498.006].
62. Sander N, Stölzl D, Fonfara M, et al. Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2024;191(3):344-350. [PMID: 38531691].
63. Guttman-Yassky E, Okragly A, Sun Z, Nickoloff BJ, Natalie CR, Gallo G, Wolf E, Eyerich K, Aparici M, Benschop RJ. Clinical measures of improvement in atopic dermatitis are correlated with reductions in relevant biomarkers in patients treated with lebrikizumab [poster]. Presented at: American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA, USA.
64. DailyMed - ADBRY- tralokinumab-ldrm injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8020b69-3001-44e2-9b5d-5f93d9aaf6e1. Accessed December 28, 2024.
65. Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768-775. [PMID: 28865094].
66. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol JEADV. 2012;26(9):1176-1193. [PMID: 22813359].
67. Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol JEADV. 2016;30(5):729-747. [PMID: 27004560].
68. Saeki H, Nakahara T, Tanaka A, et al. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016. J Dermatol. 2016;43(10):1117-1145. [PMID: 27076388].
69. Kim JE, Kim HJ, Lew BL, et al. Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Systemic Treatment. Ann Dermatol. 2015;27(5):578-592. [PMID: 26512172].
70. Rubel D, Thirumoorthy T, Soebaryo RW, et al. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. J Dermatol. 2013;40(3):160-171. [PMID: 23289827].
71. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295-299.e1-27. [PMID: 23374261].
72. Rowland K. Short-term use of oral corticosteroids was linked to increased risk for sepsis, VTE, and fractures. Ann Intern Med. 2017;167(4):JC20. [PMID: 28806801].
73. Horton DB, Xie F, Chen L, et al. Oral Glucocorticoids and Incident Treatment of Diabetes Mellitus, Hypertension, and Venous Thromboembolism in Children. Am J Epidemiol. 2021;190(3):403-412. [PMID: 32902632].
74. Arkwright PD, Motala C, Subramanian H, et al. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2013;1(2):142-151. [PMID: 24565453].
75. Injection Site Reactions From an Integrated Analysis of Phase 2 and Phase 3 Clinical Trials of Lebrikizumab Treatment in Moderate-to-Severe Atopic Dermatitis. Poster presented at Revolutionizing Atopic Dermatitis (RAD); Virtual, USA; Dates (11-13 December 2022).
76. Martora F, Patruno C, D’Ascenzo S, Napolitano M. Injection site reactions after dupilumab or tralokinumab for atopic dermatitis. J Dermatol Treat. 2024;35(1):2304027. [PMID: 38240111].
77. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-2348. [PMID: 27690741].
78. Stein Gold L. Lebrikizumab confirms a consistent safety profile in adults and adolescents with moderate-to-severe atopic dermatitis: Data from 11 trials with over 3000 patient-years of exposure. Poster Presented at Fall Clinical 2024 Las Vegas, Nevada; Oct 2024.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Lauren DeBusk, Natasha Atanaskova-Mesinkovska, Brooke Bartley, Joshua Burshtein, Michael Cameron, Theodore Daly, Lawrence Eichenfield, Dawn Merritt, Tejesh Patel, Darrell Rigel, Angela Rosenberg, Milaan Shah, Lisa Swanson, Danny Zakria, Mark Lebwohl (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.